All In Biotech

Free tool

FAERS Monitor: Xyzal

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022064 or its brand name (Xyzal, Levocetirizine Dihydrochloride). Reports on generic versions are filed under their own applications.

Reports

18,341

Serious

9,290

51% of reports

Hospitalization

3,893

Death reported

966

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,535
  • fatigue1,340
  • headache1,232
  • pruritus1,204
  • nausea1,069
  • dyspnoea1,055
  • diarrhoea990
  • somnolence926
  • dizziness823
  • arthralgia781
  • cough764
  • rash758
  • pyrexia715
  • pain712
  • off label use709

Reports by year received

View as table
YearReports
20045
200510
20066
200725
2008161
2009238
2010262
2011438
2012576
2013396
2014387
2015554
2016828
2017814
2018977
20191,693
20201,545
20211,240
20221,544
20231,669
20241,797
20251,800
20261,376

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,818 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
somnolenceSignal9265.35.03,237
pruritusSignal1,2043.63.42,294
coughSignal7643.12.91,117
pyrexiaSignal7152.42.2575
headacheSignal1,2322.32.1885
arthralgiaSignal7812.22.0492
dyspnoeaSignal1,0552.12.0655
rash7582.01.9383
fatigue1,3402.01.9668
dizziness8231.91.8354
diarrhoea9901.81.7334
nausea1,0691.51.5216
drug ineffective1,5351.31.3138
pain7121.31.260
off label use7090.90.94

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.